| Date | Title | Description | |
|---|---|---|---|
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
| 21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
| 21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Jul 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2022 | Download |
| 30 Jun 2022 | Other relevant information | The Company informs about the dividends payment | Download |
| 16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
| 14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 11 May 2022 | On business and financial situation | The Company releases the press release related to the first quarter 2022 financial result | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Nov 2012 | Composición Consejo de Administración | Download | |
| 18 Sep 2012 | Otros sobre negocio y situación financiera | Download | |
| 26 Jul 2012 | Información sobre resultados (2) | Download | |
| 26 Jul 2012 | Información sobre resultados | Download | |
| 26 Jul 2012 | Información financiera intermedia | Download |